Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 11;138(19):1786-1787.
doi: 10.1182/blood.2021013184.

Siglec-6 CAR T: magic bullet for a moving target

Sara Ghorashian  1 , Martin Pule  2
Affiliations
Editorial

Siglec-6 CAR T: magic bullet for a moving target

Sara Ghorashian et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.P. receives a salary contribution from and owns stock in Autolus Therapeutics. S.G. declares no competing financial interests.

Figures

None
CAR T-cell therapy for AML ideally targets LSCs and AML blasts, but spares HSCs and myelopoiesis. Early approaches such as targeting of CD123 (a) and CD33 (b) did not spare HSCs or myelopoiesis, resulting in aplasia. (c) More complex targeting approaches where CAR T activation is triggered only by the presence of 2 antigens can allow increased specificity. In this example, CD13 is expressed by LSC and blasts, but it is also expressed by HSCs and myeloid cells. Although TIM3 is expressed outside the hematopoietic system, it is expressed on AML cells but not on normal HSCs. (d) Finally, some antigens such as Siglec-6, which are expressed on AML cells but not on normal hematopoietic cells may allow simple and selective targeting of AML.
See this image and copyright information in PMC

Comment on

  • Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
    Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M. Jetani H, et al. Blood. 2021 Nov 11;138(19):1830-1842. doi: 10.1182/blood.2020009192. Blood. 2021. PMID: 34289026 Free PMC article.

References

    1. Jetani H, Navarro-Bailón A, Maucher M, et al. . Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML). Blood. 2021;138(19):1830-1842. - PMC - PubMed
    1. Wang QS, Wang Y, Lv HY, et al. . Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;138(19):184-191. - PMC - PubMed
    1. Mardiros A, Dos Santos C, McDonald T, et al. . T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;138(19):3138-3148. - PMC - PubMed
    1. Mardiana S, Gill S. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol. 2020;138:697. - PMC - PubMed
    1. Perna F, Berman SH, Soni RK, et al. . Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer Cell. 2017;138(19):506-519.e5. - PMC - PubMed

MeSH terms

Substances